{
    "id": "5c647c52e842deac6700001c",
    "question": "Is erythropoietin effective for treatment of amyotrophic lateral sclerosis?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to analyze the available information about erythropoietin and its effects on amyotrophic lateral sclerosis (ALS). Erythropoietin is a hormone that stimulates erythropoiesis, or red blood cell production, and is often used to treat anemia in patients with chronic kidney disease or cancer. However, its effectiveness in treating ALS is not clearly established. From Document [1], we know that erythropoietin is not directly linked to the treatment of neurodegenerative diseases like ALS. Document [2] mentions that antioxidants and other agents have been tried in ALS, but none have been shown to be effective. Document [9] mentions that nusinersen, a drug used to treat spinal muscular atrophy, has shown some benefits in patients with ALS, but this is a different condition. Document [10] discusses the clinical uses of erythropoietin, including its use in treating anemia, but does not mention its use in treating ALS. Document [11] states that erythropoietin is not effective in treating primary bone marrow disorders, which includes ALS. Based on the available information, there is no clear evidence to suggest that erythropoietin is effective for the treatment of ALS. In fact, the information suggests that ALS is a distinct condition that requires different treatment approaches. Therefore, the correct answer is B. no.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "Pharmacology_Katzung_3691",
            "title": "Pharmacology_Katzung",
            "content": "In selected patients, erythropoietin is also used to reduce the need for red blood cell transfusion in patients undergoing myelosuppressive cancer chemotherapy who have a hemoglobin level of less than 10 g/dL, and for selected patients with low-risk myelodysplastic syndromes and anemia requiring red blood cell transfusion. Patients who have disproportionately low serum erythropoietin levels for their degree of anemia are most likely to respond to treatment. Patients with endogenous erythropoietin levels of less than 100 IU/L have the best chance of response, although patients with erythropoietin levels between 100 and 500 IU/L respond occasionally. Methoxy polyethylene glycol\u2013 epoetin beta should not be used for treatment of anemia caused by cancer chemotherapy because a clinical trial found significantly more deaths among patients receiving this form of erythropoietin."
        },
        {
            "id": "InternalMed_Harrison_7820",
            "title": "InternalMed_Harrison",
            "content": "The number of reports of paraneoplastic spinal cord syndromes, such as subacute motor neuronopathy and acute necrotizing myelopathy, has decreased in recent years. This may represent a true decrease in incidence, due to improved and prompt oncologic interventions, or the identification of nonparaneoplastic etiologies. Some patients with cancer develop upper or lower motor neuron dysfunction or both, resembling amyotrophic lateral sclerosis. It is unclear whether these disorders have a paraneoplastic etiology or simply coincide with the presence of cancer. There are isolated case reports of cancer patients with motor neuron dysfunction who had neurologic improvement after tumor treatment. A search for lymphoma should be undertaken in patients with a rapidly progressive motor neuron syndrome and a monoclonal protein in serum or CSF."
        },
        {
            "id": "Neurology_Adams_8904",
            "title": "Neurology_Adams",
            "content": "The antiglutamate agent riluzole, when given orally, was shown by Bensimon and colleagues to slow the progression of ALS and improve survival in patients with disease of bulbar onset; it prolonged survival by 3 months. Antioxidants have slowed the clinical progress of ALS in limited and unconfirmed trials. Masitinib is a tyrosine kinase inhibitor that has been tried in a number of degenerative disorders and is under investigation in ALS. Some of these claims have been confirmed in several followup studies, although again, the benefit has been marginal. Several additional agents are reported to have been effective in genetic models of ALS. Among the long list of agents that have claimed, but ultimately failed, to help ALS are guanidine hydrochloride, injections of cobra venom, gangliosides, interferons, high-dose intravenous cyclophosphamide, and thyrotropin-releasing hormone."
        },
        {
            "id": "InternalMed_Harrison_9047",
            "title": "InternalMed_Harrison",
            "content": "Granulocyte and granulocyte-macrophage colony-stimulating factors are clinically useful to hasten leukocyte recovery in patients with leukopenia related to high-dose chemotherapy. Erythropoietin stimulates erythrocyte production in patients with anemia of chronic renal failure and other conditions, thus avoiding or reducing the need for transfusion. This hormone can also stimulate erythropoiesis in the autologous donor to enable additional donation."
        },
        {
            "id": "Physiology_Levy_2686",
            "title": "Physiology_Levy",
            "content": "Chapter 23. Tissue oxygenation depends on the concentration of Hgb and thus on the number of red blood cells available in the circulation. Red blood cell production (erythropoiesis) in the bone marrow is controlled by the hormone erythropoietin, which is synthesized in the kidneys by cortical interstitial cells. Although Hgb levels are normally very stable, decreased O2 delivery, low Hgb concentration, and low PaO2 stimulate the secretion of erythropoietin. This increases the production of red blood cells. Chronic renal disease damages the cortical interstitial cells and thereby suppresses their ability to synthesize erythropoietin. This causes anemia, along with decreased Hgb because of the lack of erythropoietin. Erythropoietin replacement therapy using epoetin alfa (Epogen, Procrit) or darbepoetin alfa (Aranesp) effectively increases red blood cell production."
        },
        {
            "id": "Pharmacology_Katzung_3689",
            "title": "Pharmacology_Katzung",
            "content": "erythropoietin. In most primary bone marrow disorders (aplastic anemia, leukemias, myeloproliferative and myelodysplastic disorders, etc) and most nutritional and secondary anemias, endogenous erythropoietin levels are high, so there is less likelihood of a response to exogenous erythropoietin (but see below)."
        },
        {
            "id": "Pharmacology_Katzung_3687",
            "title": "Pharmacology_Katzung",
            "content": "Erythropoietin stimulates erythroid proliferation and differentiation by interacting with erythropoietin receptors on red cell progenitors. The erythropoietin receptor is a member of the JAK/ STAT superfamily of cytokine receptors that use protein phosphorylation and transcription factor activation to regulate cellular function (see Chapter 2). Erythropoietin also induces release of reticulocytes from the bone marrow. Endogenous erythropoietin is produced primarily in the kidney. In response to tissue hypoxia, more erythropoietin is produced through an increased rate of transcription of the erythropoietin gene. This results in correction of the anemia, provided that the bone marrow response is not impaired by red cell nutritional deficiency (especially iron deficiency), primary bone marrow disorders (see below), or bone marrow suppression from drugs or chronic diseases."
        },
        {
            "id": "Pharmacology_Katzung_3040",
            "title": "Pharmacology_Katzung",
            "content": "Among the compounds that have been investigated as potential neuroprotective agents to slow disease progression are antioxidants, antiapoptotic agents, glutamate antagonists, intraparenchymally administered glial-derived neurotrophic factor, and anti-inflammatory drugs. None of these agents has been shown to be effective in this context, however, and their use for therapeutic purposes is not indicated at this time. Coenzyme Q10, creatine, pramipexole, and pioglitazone have not been found to be effective despite early hopes to the contrary. The possibility that rasagiline has a protective effect was discussed earlier. Active and passive immunization against \u03b1-synuclein is being explored."
        },
        {
            "id": "InternalMed_Harrison_5388",
            "title": "InternalMed_Harrison",
            "content": "ethical concerns. Nevertheless, clinical trials of fetal neural stem cells have commenced in amyotrophic lateral sclerosis (ALS), stroke, and several other disorders. Transdifferentiation of MSCs and ASCs into neural stem cells, and vice versa, has been reported by numerous investigators, and clinical trials of such cells have begun for a number of neurologic diseases. Clinical trials of a conditionally immortalized human cell line and of USCs in stroke are also in progress. Because of the incapacitating nature of neural disorders and the limited endogenous repair capacity of the nervous system, clinical trials of stem cells in neurologic disorders have been particularly numerous, including trials in spinal cord injury, multiple sclerosis, epilepsy, Alzheimer\u2019s disease, ALS, acute and chronic stroke, numerous genetic disorders, traumatic brain injury, Parkinson\u2019s disease, and others. In diseases such as ALS, possible benefits are more likely to be due to indirect trophic effects than"
        },
        {
            "id": "Neurology_Adams_9011",
            "title": "Neurology_Adams",
            "content": "Mercuri E, Darras BT, Chiriboga CA, et al: Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 378:625, 2018. Mesulam MM: Primary progressive aphasia\u2014a language-based dementia. N Engl J Med 349:1535, 2003. Mesulam MM: Slowly progressive aphasia without generalized dementia. Ann Neurol 11:592, 1982. Miller RG, Jackson CE, Kasarskis EJ, et al: Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: Multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73:1227, 2009a. Miller RG, Jackson CE, Kasarskis EJ, et al: Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73:1218, 2009b."
        },
        {
            "id": "Pharmacology_Katzung_3685",
            "title": "Pharmacology_Katzung",
            "content": "Erythropoietin, a 34to 39-kDa glycoprotein, was the first human hematopoietic growth factor to be isolated. It was originally purified from the urine of patients with severe anemia. Recombinant human erythropoietin (rHuEPO, epoetin alfa) is produced in a mammalian cell expression system. After intravenous administration, erythropoietin has a serum half-life of 4\u201313 hours in patients with chronic renal failure. It is not cleared by dialysis. It is measured in international units (IU). Darbepoetin alfa is a modified form of erythropoietin that is more heavily glycosylated as a result of changes in amino acids. Darbepoetin alfa has a twofold to threefold longer half-life than epoetin alfa. Methoxy polyethylene glycol\u2013epoetin beta is an isoform of erythropoietin covalently attached to a long polyethylene glycol polymer. This long-lived recombinant product is administered as a single intravenous or subcutaneous dose at 2-week or monthly intervals, whereas epoetin alfa is generally"
        },
        {
            "id": "Pharmacology_Katzung_3688",
            "title": "Pharmacology_Katzung",
            "content": "Normally, an inverse relationship exists between the hematocrit or hemoglobin level and the serum erythropoietin level. Nonanemic individuals have serum erythropoietin levels of less than 20 IU/L. As the hematocrit and hemoglobin levels fall and anemia becomes more severe, the serum erythropoietin level rises exponentially. Patients with moderately severe anemia usually have erythropoietin levels in the 100\u2013500 IU/L range, and patients with severe anemia may have levels of thousands of IU/L. The most important exception to this inverse relationship is in the anemia of chronic renal failure. In patients with renal disease, erythropoietin levels are usually low because the kidneys cannot produce the growth factor. These are the patients most likely to respond to treatment with exogenous erythropoietin. In most primary bone marrow disorders (aplastic anemia, leukemias, myeloproliferative and myelodysplastic disorders, etc) and most nutritional and secondary anemias, endogenous"
        },
        {
            "id": "Pharmacology_Katzung_3690",
            "title": "Pharmacology_Katzung",
            "content": "The availability of erythropoiesis-stimulating agents (ESAs) has had a significant positive impact for patients with several types of anemia (Table 33\u20134). The ESAs consistently improve the hematocrit and hemoglobin level, often eliminate the need for transfusions, and reliably improve quality of life indices. The ESAs are used routinely in patients with anemia secondary to chronic kidney disease. In patients treated with an ESA, an increase in reticulocyte count is usually observed in about 10 days and an increase in hematocrit and hemoglobin levels in 2\u20136 weeks. Dosages of ESAs are adjusted to maintain a target hemoglobin up to, but not exceeding, 10\u201312 g/dL. To support the increased erythropoiesis, nearly all patients with chronic kidney disease require oral or parenteral iron supplementation. Folate supplementation may also be necessary in some patients."
        },
        {
            "id": "InternalMed_Harrison_30706",
            "title": "InternalMed_Harrison",
            "content": "Anemia should be corrected with erythropoietin, administered subcutaneously at doses of 25\u201375 U/kg three times per week. The hematocrit increases after 2\u20136 weeks. A weekly maintenance dose is usually necessary. However, the increased intravascular volume that accompanies the rise in hematocrit can exacerbate supine hypertension."
        },
        {
            "id": "Obstentrics_Williams_7697",
            "title": "Obstentrics_Williams",
            "content": "For treatment, adequate iron stores must be ensured. Recombinant eythropoietin has been used successfully to treat anemia stemming from chronic disease (Weiss, 2005). In pregnancies complicated by chronic renal insuiciency, recombinant erythropoietin is usually considered when the hematocrit approximates 20 percent (Cyganek, 2011; Ramin, 2006). One worrisome side efect of this agent is hypertension, which is already prevalent in women with renal disease. Red cell aplasia and antierythropoietin antibodies have also reported (Casadevall, 2002; McCoy, 2008). These anemias are characterized by blood and bone-marrow abnormalities from impaired DNA synthesis. This leads to large cells with arrested nuclear maturation, whereas the cytoplasm matures more normally. Worldwide, the prevalence of megaloblastic anemia during pregnancy varies considerably. It is rare in the United States."
        },
        {
            "id": "InternalMed_Harrison_7771",
            "title": "InternalMed_Harrison",
            "content": "Most patients with erythrocytosis have an elevated hematocrit (>52% in men, >48% in women) that is detected on a routine blood count. Approximately 3% of patients with renal cell cancer, 10% of patients with hepatoma, and 15% of patients with cerebellar hemangioblastomas have erythrocytosis. In most cases, the erythrocytosis is asymptomatic. Patients with erythrocytosis due to a renal cell cancer, hepatoma, or CNS cancer should have measurement of red cell mass. If the red cell Cancers Typically Associated Syndrome Proteins with Syndrome Abbreviations: G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin. mass is elevated, the serum erythropoietin level should be measured. Patients with an appropriate cancer, elevated erythropoietin levels, and no other explanation for erythrocytosis (e.g., hemoglobinopathy that causes increased O2 affinity; Chap. 77) have the paraneoplastic syndrome."
        },
        {
            "id": "Pediatrics_Nelson_3184",
            "title": "Pediatrics_Nelson",
            "content": "Treatment. In an otherwise healthy child, a therapeutic trial of iron is the best diagnostic study for iron deficiency as long as the child is re-examined and a response is documented. The response to oral iron includes rapid subjective improvement, especially in neurologic function (within 24 to 48 hours) and reticulocytosis (48 to 72 hours); increase in hemoglobin levels (4 to 30 days); and repletion of iron stores (in 1 to 3 months). The usual therapeutic dose of 4 to 6 mg/day 10\u201312 nc/nc \u2193 Fe2+ absent, erythroid hyperplasia <12 8\u201310 hypo/nc \u2193 Fe2+ absent, erythroid hyperplasia <12 <8 hypo/micro* \u2193 Fe2+ absent, erythroid hyperplasia <12"
        },
        {
            "id": "Neurology_Adams_5385",
            "title": "Neurology_Adams",
            "content": "Better defined is subacute motor neuronopathy that occurs as a remote effect of bronchogenic carcinoma, Hodgkin disease, and other lymphomas as mentioned earlier in the discussion of encephalomyelitis (Schold et al). Some cases take the form of a relatively benign, purely motor weakness of the limbs, the course and severity of which are independent of the underlying neoplasm. Other cases are severe and progressive, causing respiratory failure and death, thus simulating amyotrophic lateral sclerosis (ALS); some of these will have the anti-Hu antibody (Verma et al; Forsyth et al). The basic neuropathologic change is a depletion of anterior horn cells; also seen are inflammatory changes and neuronophagia as in chronic poliomyelitis. The few autopsied cases have shown gliosis of the posterior columns, pointing to an asymptomatic affection of the primary sensory neuron, as well as a reduction in the number of Purkinje cells."
        },
        {
            "id": "InternalMed_Harrison_8004",
            "title": "InternalMed_Harrison",
            "content": "level of renal failure. By contrast, patients with cytokines. Through the release of tumor necrosis factor (TNF) and diabetes or myeloma have more severe EPO deficiency for a given level interferon \u03b3 (IFN-\u03b3), neoplasms and bacterial infections suppress of renal failure. erythropoietin (EPO) production and the proliferation of erythroid Assessment of iron status provides information to distinguish the progenitors (erythroid burst-forming units and erythroid colony-anemia of CKD from the other forms of hypoproliferative anemia forming units [BFU/CFU-E]). The mediators in patients with vasculitis (Table 126-6) and to guide management. Patients with the anemia of and rheumatoid arthritis include interleukin 1 (IL-1) and IFN-\u03b3. The red CKD usually present with normal serum iron, TIBC, and ferritin levarrows indicate sites of inflammatory cytokine inhibitory effects. RBC, els. However, those maintained on chronic hemodialysis may develop red blood cell. iron deficiency from blood loss"
        },
        {
            "id": "Neurology_Adams_228",
            "title": "Neurology_Adams",
            "content": "of stroke, multiple sclerosis, and amyotrophic lateral sclerosis. Although the degree of functional deficit does not precisely correlate with the degree of electrophysiologic change, one expects that refinements of this technique may be useful in evaluating the status of the corticospinal motor system as well as other cortically based functions."
        },
        {
            "id": "Neurology_Adams_8986",
            "title": "Neurology_Adams",
            "content": "Creutzfeldt HG: Uber eine eigenartige herdformige Erkrankung des Zentralnervensystems. Z Gesamte Neurol Psychiatr 57:1, 1920. Cross HE, McKusick VA: The mast syndrome. Arch Neurol 16:1, 1967. Cudkowicz ME, McKenna-Yasek D, Chen C, et al: Limited corticospinal tract involvement in amyotrophic lateral sclerosis subjects with the A4V mutation in the copper/zinc superoxide dismutase gene. Ann Neurol 43:703, 1998. Cummings J, Isaacson S, Mills R , et al.: Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383:533, 2014. Curtis AR, Fey C, Morris CM, et al: Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 28:350, 2001. Cury R, Galhardoni R, Fontoff ET, et al: Effects of deep brain stimulation on pain and other nonmotor symptoms of Parkinson disease. Neurology 83:1403, 2014."
        },
        {
            "id": "Pharmacology_Katzung_3692",
            "title": "Pharmacology_Katzung",
            "content": "Erythropoietin is one of the drugs commonly used illegally by endurance athletes to enhance performance. Other methods such as autologous transfusion of red cells or use of androgens also have been used to increase hemoglobin. \u201cBlood doping\u201d constitutes a serious health risk to athletes and as a form of cheating is universally banned and routinely tested for in athletic events. The most common adverse effects of erythropoietin are hypertension and thrombotic complications. ESAs increase the risk of serious cardiovascular events, thromboembolic events, stroke, and mortality in clinical studies when given to support hemoglobin TABLE 33\u20134 Clinical uses of hematopoietic growth factors and agents that mimic their actions."
        },
        {
            "id": "Obstentrics_Williams_4211",
            "title": "Obstentrics_Williams",
            "content": "concomitant neonatal erythropoietin therapy for neuroprophylaxis have reported conlicting results (Fauchere, 2015; Ivf all a, 2017). Preliminary data from one multicenter trial of maternal alopurinol therapy indicate some mitigation of cerebral damage caused by hypoxia and ischemia (Kaandorp,r2013)."
        },
        {
            "id": "Neurology_Adams_7356",
            "title": "Neurology_Adams",
            "content": "As mentioned under \u201cAcute Multiple Sclerosis,\u201d there may be a role for plasma exchange (see Weinshenker et al, 1999; Rodriguez et al) and perhaps immunoglobulin in fulminant cases. One limited trial has shown possible but mild benefit in patients with relapsing\u2013remitting disease of monthly infusions of intravenous immunoglobulin (0.2 g/kg) for 2 years (Fazekas et al)."
        },
        {
            "id": "Neurology_Adams_9803",
            "title": "Neurology_Adams",
            "content": "conditions such as neuropathy and amyotrophic lateral sclerosis (ALS) may be mistakenly attributed to this innocuous finding. The levels return to normal within a few months of abstaining from fish."
        },
        {
            "id": "InternalMed_Harrison_8412",
            "title": "InternalMed_Harrison",
            "content": "Abbreviations: 2,3-BPG, 2,3-bisphosphoglycerate; VHL, von Hippel-Lindau. cell mass; thus, red cell mass and plasma volume determinations are necessary to establish the presence of an absolute erythrocytosis and to distinguish this from relative erythrocytosis due to a reduction in plasma volume alone (also known as stress or spurious erythrocytosis or Gaisb\u00f6ck\u2019s syndrome). Figure 77-18 illustrates a diagnostic algorithm for the evaluation of suspected erythrocytosis. Assay for JAK2 mutations in the presence of a normal arterial oxygen saturation provides an alternative diagnostic approach to erythrocytosis when red cell mass and plasma volume determinations are not available; a normal serum erythropoietin level does not exclude the presence of PV, but an elevated erythropoietin level is more consistent with a secondary cause for the erythrocytosis."
        },
        {
            "id": "Neurology_Adams_4135",
            "title": "Neurology_Adams",
            "content": "hypoxic-hypotensive encephalopathy, amyotrophic lateral sclerosis, and multiple sclerosis, as already indicated; but in a number of less-common processes, such as progressive supranuclear palsy and Wilson disease, it may be quite a prominent feature. Abrupt onset, of course, points to vascular disease."
        },
        {
            "id": "InternalMed_Harrison_8437",
            "title": "InternalMed_Harrison",
            "content": "No specific therapy exists for PMF. The causes for anemia are multifarious and include ineffective erythropoiesis uncompensated by splenic extramedullary hematopoiesis, hemodilution due to splenomegaly, splenic sequestration, blood loss secondary to thrombocytopenia or portal hypertension, folic acid deficiency, systemic inflammation, and autoimmune hemolysis. Neither recombinant erythropoietin nor androgens such as danazol have proven to be consistently effective as therapy for anemia. Erythropoietin may worsen splenomegaly and will be ineffective if the serum erythropoietin level is >125 mU/L. Given the inflammatory milieu that characterizes PMF, corticosteroids can ameliorate anemia as well as constitutional symptoms such as fever, chills, night sweats, anorexia, and weight loss, and low-dose thalidomide together with prednisone has proved effective as well. Thrombocytopenia can be due to impaired marrow function, splenic sequestration, or autoimmune destruction"
        },
        {
            "id": "Pharmacology_Katzung_2042",
            "title": "Pharmacology_Katzung",
            "content": "neurotransmitter release, thereby regulating synaptic plasticity, the process of synapse strengthening that underlies learning and memory. Because aberrant NMDA receptor activation and excessive NO synthesis is linked to excitotoxic neuronal death in several neurologic diseases, including stroke, amyotrophic lateral sclerosis, and Parkinson\u2019s disease, therapy with NOS inhibitors may reduce neuronal damage in these conditions. However, clinical trials have not clearly supported any benefit of NOS inhibition, which may reflect nonselectivity of the inhibitors, resulting in inhibition of the beneficial effects of eNOS."
        },
        {
            "id": "Neurology_Adams_9987",
            "title": "Neurology_Adams",
            "content": "(ALS) or transverse myelopathy (most patients have some degree of weakness and spasticity of the legs). However, we have encountered cases of asymmetric and profound atrophic weakness of the arms that began almost two decades after the shock and progressed over many years without long tract signs, both with a previously presumed diagnosis of amyotrophic lateral sclerosis. In contrast to injuries caused by high current, which affects mainly the spinal white matter (see earlier), it is the gray matter that is injured in cases of spinal atrophic paralysis, at least as judged from the clinical effects."
        },
        {
            "id": "Neurology_Adams_1729",
            "title": "Neurology_Adams",
            "content": "Treatment According to Abbott and to Mitts and others, aspirin is useful in the treatment of paroxysms of secondary erythromelalgia and of some primary cases as well; others had recommended methysergide, which has fallen out of use because of retroperitoneal and cardiac valvular fibrosis. Even small doses of aspirin provide relief within an hour, lasting for several days, a feature that is diagnostic. Sano and colleagues report that cyclosporine was of great benefit in a case of familial erythromelalgia that had not responded to other medications."
        },
        {
            "id": "InternalMed_Harrison_30586",
            "title": "InternalMed_Harrison",
            "content": "Several websites provide valuable information on ALS including those offered by the Muscular Dystrophy Association (www.mdausa.org), the Amyotrophic Lateral Sclerosis Association (www.alsa.org), and the World Federation of Neurology and the Neuromuscular Unit at Washington University in St. Louis (www.neuro.wustl.edu). Stanley B. Prusiner, Bruce L. Miller"
        }
    ],
    "scores": [
        0.024618735695350714,
        0.022548946531504674,
        0.02205494277412086,
        0.021653624594801066,
        0.02154904621145215,
        0.019704911667637354,
        0.018624393624393623,
        0.01851915720240714,
        0.01838731443994602,
        0.01837336704593342,
        0.01774915573706118,
        0.017679127725856697,
        0.017336309523809525,
        0.017323775388291517,
        0.01644736842105263,
        0.01631124650926631,
        0.01615833874107722,
        0.015563732882910056,
        0.01551083962151156,
        0.015225878416062464,
        0.015159747880895457,
        0.015106569984618765,
        0.015060737646347496,
        0.014833059660645867,
        0.014743589743589743,
        0.014681295715778475,
        0.014345794392523363,
        0.014228255404725994,
        0.014030612244897957,
        0.013999438149639479,
        0.013952413952413954,
        0.013914299470389985
    ]
}